Global Innovative Platforms Appoints David R. Wells as Fractional CFO
News related to:Global Innovative Platforms, Inc · 2 min read
SANFORD, FL, UNITED STATES, October 6, 2026 /CourierPR/ -- Global Innovative Platforms (GIPL) has appointed David R. Wells as its Fractional Chief Financial Officer, effective October 1, 2026. This move is aimed at bolstering the company's financial infrastructure as it advances its VetBreath Analytics platform.
Wells brings over three decades of experience in finance, operations, and administration, primarily from roles in medical device and technology companies. In his new role, he will oversee the company's accounting and financial reporting functions, supporting SEC reporting, financial planning, cash flow planning, and financial modeling.
Since July 2021, Wells has been the owner of Atlas Bookkeeping, LLC, providing CFO advisory services to both public and private companies. From August 2023 to May 2025, he served as Chief Financial Officer of Envoy Medical, Inc. (Nasdaq: COCH). From June 2021 to September 2022, he held the same position at GHS Investments, LLC, a private equity fund. Additionally, since December 2022, Wells has served on the Board of Directors of HeartSciences, Inc. (Nasdaq: HSCS).
Wells provides his services to GIPL through Atlas Bookkeeping, LLC under a Services Agreement dated October 1, 2026. The agreement is detailed in the company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
GIPL is a publicly traded company focused on developing a non-invasive, breath-based diagnostic platform for veterinary use. The platform combines breath capture, gas chromatography, and AI and chemometric modeling to analyze volatile organic compounds, initially focusing on canine heartworm detection. The technology is in the development and validation stage, and the company intends to evaluate its potential application to additional diseases and species over time.
The company's forward-looking statements include expectations regarding the development of its VetBreath Analytics platform, potential revenue growth, and use of proceeds from any financing activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.
Global Innovative Platforms, Inc. continues to advance its innovative technologies and aims to provide reliable and non-invasive diagnostic solutions for the veterinary industry.